GlobeNewswire

RapidFire Tools, Inc. Launches Its First Channel Programme, Offering Resources to Help MSPs Profit from GDPR Compliance

Dela

The Audit Guru for GDPR(TM) Partner Programme Includes Training, Onboarding Assistance, Marketing Materials, NFR Products, and an Online Management Portal

ATLANTA, April 16, 2018 (GLOBE NEWSWIRE) -- RapidFire Tools Inc., the developers of the powerful Network Detective suite of IT assessment and compliance tools, has launched an Authorized Reseller Partner Programme in coordination with its new Audit Guru for GDPR tool. The programme marks the first time RapidFire Tools is selling one of its products exclusively through a channel of MSP partners. The new product is designed to help organisations become compliant, and remain compliant, with the sweeping EU General Data Protection Regulation (GDPR). The regulation applies to any organisation that collects and processes personal information on people who reside within in the European Union. MSPs will have the option of simply reselling Audit Guru for GDPR to their end-user clients, or offering it along with value-added consulting and ongoing compliance management services. The GDPR takes effect on 25 May 2018.

The Audit Guru for GDPR Partner Programme is available to MSPs worldwide. While GDPR primarily affects MSPs in the EU, service providers in North America and other regions in the world whose clients service or do business with customers in the EU are also impacted. The new programme provides MSPs with everything they need to create a profitable GDPR compliance practice, including:

  • Extensive product training
  • A not-for-resale Audit Guru license for MSPs to use on their own networks
  • A second Audit Guru license to resell to their first client
  • A web-based product management portal to provision and manage the tool through a consolidated interface, or a "single pane of glass"
  • White-labelled marketing materials to help MSPs sell the new offering
  • One-on-one assistance to help MSPs onboard their first Audit Guru implementations
  • Unlimited technical support

"GDPR will have a considerable impact on IT everywhere," confirms Michael Mittel, president of RapidFire Tools. "The EU represents a significant percentage of the global economy, and any organisation on the planet that maintains personal information about individuals inside the EU are required to comply with these stringent new rules."

Audit Guru for GDPR is the first purpose-built software appliance to automatically collect the data required for a proper initial GDPR audit, as well as the required on-going compliance checks. The tool will automatically generate the documentation and reporting required under the standard. Audit Guru produces dynamic, step-by-step instructions and worksheets needed to complete the assessment process.

"Until now, our tools have been sold to MSPs for internal use as part of their business development and service delivery," explained Mittel. "This launch marks a paradigm shift, wherein we've designed a product that MSPs can sell directly to the network owner. We're relying 100 percent on our MSP channel customers, whose relationships in the SMB community will quickly bring Audit Guru to market."

In addition to healthy potential margins on the resale of Audit Guru appliance subscriptions, MSPs can gain additional revenue through value-added GDPR services, ranging from simple management of the appliances, up to fully managed and ongoing GDPR Compliance-as-a-Service offerings-all supported by RapidFire Tools' services. "The success of these MSPs is not left to chance. Our Authorized Reseller Partner Programme vests us in every aspect of the process, to ensure that MSPs are well positioned to profit," Mittel added.

"We believe every organisation is going to need a product like Audit Guru," said Mark Winter, RapidFire Tools' vice president of sales. "Everything in the programme is designed to help our MSPs get up-to-speed as quickly as possible to sell Audit Guru for GDPR into their existing client sites. MSPs who partner with us can create a lucrative enhancement to their portfolios, in addition to using the tool to land new clients."

Visit https://www.rapidfiretools.com/auditguru/ or call 678-323-1300, ext. 2.

About  RapidFire Tools

RapidFire Tools, Inc is the leading global supplier of business-building technology tools for MSPs to help them close more business, offer more services, keep more customers, and make more money. The company's offerings include: a complete set of IT Assessment, Documentation and Reporting tools; tools for IT Compliance Process Automation; and tools for Insider Cyber Threat Detection & Alerting. The new Audit Guru for GDPR tool helps MSPs and internal IT professionals automate and streamline the GDPR compliance process, to help align end-customers with the technology policies required by the new EU General Data Protection Regulation. European distributors for the Audit Guru for GDPR include: Achab (Italy), Prianto (UK), and Upstream (Denmark, Iceland, Finland, Norway, Sweden).

Contact: Bob Vogel
RapidFire Tools, Inc.
bvogel@rapidfiretools.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RapidFire Tools, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum